Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01205438 · ClinicalTrials.gov registry record · Phase 3
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,124
- Enrollment target
NCT01205438 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,124 participants.
The verdict
NCT01205438, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,124 participants
- Enrollment target
Study Summary
The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two different doses of LY2127399 administered in addition to standard of care therapy in participants with active SLE.
Interventions
- DRUG LY2127399
- DRUG Placebo every 2 weeks
- DRUG Placebo every 4 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,124 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01205438
The ClinicalTrials.gov registry entry for NCT01205438 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LY2127399 is the first listed.
NCT01205438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01205438 about?
NCT01205438 is a clinical study titled "A Study of LY2127399 in Participants With Systemic Lupus Erythematosus". The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two different doses of LY2127399 administered in addition to standard of care therapy in participants with active SLE.
What is the current status of trial NCT01205438?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,124 participants. The study started on 2011-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01205438?
The interventions under investigation include: LY2127399 (DRUG), Placebo every 2 weeks (DRUG), Placebo every 4 weeks (DRUG).
Who is sponsoring clinical trial NCT01205438?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.